Embedding Inclusive Research
In Ophthalmology
Smiling photo of Manuel Amador, M.D., Senior Medical Director, Ophthalmology,  U.S. Medical & Government Affairs, Genentech, 2023 Changemaker Award-Winner

Vision loss is often a result of Diabetic Macular Edema (DME), a preventable condition and leading cause of blindness that disproportionately affects Black and Hispanic/Latinx patients. We are partnering across the ophthalmology community to increase diversity, equity, and inclusion in ophthalmology research so all communities can have access to the eye care they need.

Our Phase IV Elevatum clinical study builds on learnings from our CHIMES study by expanding inclusion criteria, offering transportation support and addressing the inadequate representation of Black, Hispanic/Latinx and other historically excluded communities.

Through our strong community partnership and unwavering aspirations to provide culturally relevant information, we successfully accelerated the enrollment of Black and Hispanic/Latinx patients in the Elevatum study, paving the way for groundbreaking advancements.
Our people data
As part of our commitment to Diversity & Inclusion, we are sharing enterprise-wide data related to our gender representation, race/ethnicity representation, and pay practices.
Answer The Call
We are looking for transformative visionaries like you to improve lives, patient care, and health equity. Your career is at Genentech.
Join Us
Genentech Logo
Genentech Logo
© 2023 Genentech USA, Inc. All rights reserved. This site is intended for US residents only.